{
  "docId": "019de070-35c1-7439-bbdc-1b157563e1ac",
  "docSlug": "efb4ac2b8ef2465cd20aa5f0f0b26fe6",
  "documentTitle": "Poseida Therapeutics | IPO Presentation Deck | 34 slides",
  "authorId": "poseida-therapeutics",
  "authorName": "Poseida Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 34,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "unfair_advantage",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-35c1-7439-bbdc-1b157563e1ac/14",
  "deckHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac",
  "deckJsonHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac.json",
  "deckAnchorHref": "/decks/019de070-35c1-7439-bbdc-1b157563e1ac#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "High Percentage of Tscm Cells",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a28abcd-b680-4094-bb08-c57b0d2b321f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.67,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Fully Allogeneic",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b8fc247-9d47-4238-9372-45bd5b7809a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.36,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Outpatient Dosing",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a642960a-16ff-4bce-8493-79efdd6d7598",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.26,
        "x": 0.06,
        "y": 0.42
      },
      "kind": "list",
      "text": "piggyBac preferentially inserts into Tscm – virus does not; Cas-CLOVER can efficiently edit resting T-cells to preserve Tscm; Strong patent position on methods and composition of matter in Tscm T-cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f833e83-46cb-4422-95a5-b991d5ab86b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.26,
        "x": 0.37,
        "y": 0.42
      },
      "kind": "list",
      "text": "Expanded commercial reach; Dramatic reduction in cost; Necessary to expand CAR-T beyond oncology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "594ac2ac-eb16-4621-9ea3-003802c469e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.26,
        "x": 0.68,
        "y": 0.42
      },
      "kind": "list",
      "text": "Ability to address graft vs host and host vs graph; Avoid need to immunosuppress patients as with competitor partially allogeneic CAR-Ts; Booster molecule to increase yield and reduce cost",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "741a51b4-4f84-4e65-8ca6-0072bb8961d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Poseida's CAR-T Product Candidates Can Potentially Address the Limitations of Current Competitor Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3627e54e-fc12-4f67-9229-f3144b7189bb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 11,
      "beatId": "e01fc233-3e21-43db-96cd-4c2c3ec10517",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Description of pipeline and product candidates, including CAR-T and gene therapy programs",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7c1fa860-c3ac-4d04-9727-4ec067dac855",
      "evidence": "Not All T-Cells are Created Equally: The Importance of Stem Cell Memory T Cells (Tscm)",
      "position": 0,
      "objective": "What are the limitations of current competitor therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}